Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2002-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.46.4.1032-1037.2002PMID 11897586PMCID PMC127116
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi

  2004cited by this paper
• Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia

  2001cited by this paper
• International Surveillance of Bloodstream Infections Due toCandida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program

  2001cited by this paper
• In Vitro Fungicidal Activities of Voriconazole, Itraconazole, and Amphotericin B against Opportunistic Moniliaceous and Dematiaceous Fungi

  2001cited by this paper
• Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients.

  2001cited by this paper
• Optimal Susceptibility Testing Conditions for Detection of Azole Resistance in Aspergillus spp.: NCCLS Collaborative Evaluation

  2001cited by this paper
• Aspergillosis case-fatality rate: systematic review of the literature.

  2001cited by this paper
• Trends in Antifungal Drug Susceptibility of Cryptococcus neoformans Isolates in the United States: 1992 to 1994 and 1996 to 1998

  2001cited by this paper
• Interpretive criteria of ceftibuten disk diffusion susceptibility tests according to the DIN 58 940 method.

  2001cited by this paper
• Uncommon opportunistic fungi: new nosocomial threats.

  2001cited by this paper
• Critical assessment of issues in the diagnosis of invasive aspergillosis.

  2001cited by this paper
• The VISA/GISA problem: therapeutic implications.

  2001cited by this paper
• Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children.

  2001cited by this paper
• Burden of aspergillosis-related hospitalizations in the United States.

  2000cited by this paper
• In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, againstAspergillus and Candida

  2000cited by this paper
• Hospitals and clinics

  2000cited by this paper
• Introduction to antifungal drugs.

  2000cited by this paper
• Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998

  2000cited by this paper
• Pharmacokinetics of SCH 56592, a New Azole Broad-Spectrum Antifungal Agent, in Mice, Rats, Rabbits, Dogs, and Cynomolgus Monkeys

  2000cited by this paper
• The epidemiology of candidemia in two United States cities: results of a population-based active surveillance.

  1999cited by this paper
• International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe).

  1999cited by this paper
• Current and Emerging Azole Antifungal Agents

  1999cited by this paper
• Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.

  1999cited by this paper
• In Vitro Activities of BMS-207147 against Over 600 Contemporary Clinical Bloodstream Isolates of Candida Species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America

  1999cited by this paper
• The epidemiology of invasive mycoses--narrowing the gap.

  1998cited by this paper
• An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group.

  1998cited by this paper
• International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and Antifungal Susceptibilities of Isolates Collected in 1997 in the United States, Canada, and South America for the SENTRY Program

  1998cited by this paper
• Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts

  1998cited by this paper
• The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance.

  1998cited by this paper
• Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi.

  1998cited by this paper
• POTENTIAL NEW ANTIFUNGAL AGENTS

  1997cited by this paper
• Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis

  1997cited by this paper
• In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp

  1997cited by this paper
• In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens

  1997cited by this paper
• Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs

  1997cited by this paper
• In vitro evaluation of voriconazole against some clinically important fungi

  1997cited by this paper
• Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus

  1997cited by this paper
• The new fungal opportunists are coming.

  1996cited by this paper
• Trends in the postmortem epidemiology of invasive fungal infections at a university hospital.

  1996cited by this paper
• Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients.

  1996cited by this paper
• Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery.

  1995cited by this paper
• National Committee for Clinical Laboratory Standards.

  1980cited by this paper

• Antifungal Susceptibility Trends Among Filamentous Fungi: An Epidemiological Evaluation on Aspergillus spp., Fusarium spp., and Scedosporium spp. from Southern Italy.

  2026cites this paper
• Microemulsion-Loaded Chitosan Transdermal Films of Posaconazole for Targeted Aspergillosis Therapy

  2025cites this paper
• Exophiala Bloodstream Infections in Humans—A Narrative Review

  2025cites this paper
• Fused and Substituted Piperazines as Anticancer Agents: A Review

  2025cites this paper
• Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial.

  2025cites this paper
• Efficacy of two novel antifungal lipopeptides, AF4 and AF5 of bacillomycin D family in murine models of invasive candidiasis, cryptococcosis, and aspergillosis

  2024cites this paper
• Utility of Itraconazole in Combination with Liposomal Amphotericin B in Rhizopus oryzae Associated Mucormycosis–An Exploratory Study

  2024cites this paper
• Azole Combinations and Multi-Targeting Drugs That Synergistically Inhibit Candidozyma auris

  2024cites this paper
• An updated list of eumycetoma causative agents and their differences in grain formation and treatment response

  2024cites this paper
• Discovery of Novel Tetrazoles Featuring a Pyrazole Moiety as Potent and Highly Selective Antifungal Agents

  2023cites this paper
• Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine

  2023cites this paper
• An update on the global treatment of invasive fungal infections.

  2023cites this paper
• Mass spectrometry-based proteomics as an emerging tool in clinical laboratories

  2023cites this paper
• 1,3-Thiazole Derivatives as a Promising Scaffold in Medicinal Chemistry: A Recent Overview.

  2023cites this paper
• A Prospective Study to Evaluate the Effect of Therapeutic Drug Monitoring-Based Posaconazole Prophylaxis on Invasive Fungal Infection Rate During Acute Myeloid Leukemia Induction Therapy

  2023cites this paper
• Thiadiazole and Thiazole Derivatives as Potential Antimicrobial Agents.

  2023cites this paper
• The Specific Binding and Promotion Effect of Azoles on Human Aldo-Keto Reductase 7A2

  2023cites this paper
• In vitro antifungal susceptibility of Fusarium species and Aspergillus fumigatus cultured from eleven horses with fungal keratitis.

  2022cites this paper
• Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents

  2022cites this paper
• Acremonium species skin infection in a female French bulldog

  2022cites this paper
• Discovery of Novel Orally Bioavailable Triazoles with Potent and Broad-Spectrum Antifungal Activity In Vitro and In Vivo.

  2022cites this paper
• Molecular identification, phylogeny and antifungal susceptibilities of dematiaceous fungi isolated from human keratomycosis.

  2022cites this paper
• Another Perspective on Black Fungus Disease in Veterinary

  2022cites this paper
• Novel 1, 2, 4-Triazoles as Antifungal Agents

  2022cites this paper
• “ZYGOMYCOSIS (MUCORMYCOSIS) AND REVIEW OF THE LITERATURE”

  2022cites this paper
• Mycetoma due to Aspergillus flavus in a diabetic patient: Case report and literature review

  2022cites this paper
• Synthetic antifungal compounds

  2021cites this paper
• Base-Catalyzed Three-Component Reaction between Chalcones, Isothiocyanates, and Sulfur: Access to Thiazole-2-thiones.

  2021cites this paper
• In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years.

  2021cites this paper
• The Environmental Spread of Aspergillus terreus in Tyrol, Austria

  2021cites this paper
• Identification and in vitro antifungal susceptibility of causative agents of onychomycosis due to Aspergillus species in Mashhad, Iran

  2021cites this paper
• Comparative activity of posaconazole and systemic azole agents against clinical isolates of filamentous fungi from a global surveillance programme

  2021cites this paper
• Mucormycosis: A deadly black fungus infection among COVID-19 patients in India

  2021cites this paper
• Antifungal Susceptibility Testing of Pathogenic Aeromycoflora Isolated from Kathmandu

  2021cites this paper
• Cerebral mucormycosis: intranasal route to deliver amphotericin B for effective management?

  2021cites this paper
• Antifungal Susceptibility Testing: A Primer for Clinicians

  2021cites this paper
• Exophiala dermatitidis as a cause of central line associated bloodstream infection in an infant: Case report and literature review.

  2020cites this paper
• Study on invasive aspergillosis using galactomannan enzyme immunoassay and determining antifungal drug susceptibility among hospitalized patients with hematologic malignancies or candidates for organ transplantation.

  2020cites this paper
• Antifungal drugs: An updated review of central nervous system pharmacokinetics

  2020cites this paper
• Long term management challenges in diabetic patients with rhino-orbito-cerebral mucormycosis

  2020cites this paper
• An Overview of Piperazine Scaffold as Promising Nucleus for Different Therapeutic Targets.

  2020cites this paper
• Platelet volume indices: markers of carotid atherosclerosis in type 2 diabetes mellitus?

  2020cites this paper
• Corneal Pharmacokinetics of Voriconazole and Posaconazole following Intrastromal Injection and Posaconazole Eye Drops Instillation in Rats

  2020cites this paper
• Synthesis and characterization of ecofriendly silver nanoparticles combined with yttrium oxide (Ag-Y2O3) nanocomposite with assorted adsorption capacity for Cu(II) and Cr(VI) removal: A mechanism perspective

  2019cites this paper
• Mucormycosis

  2019cites this paper
• Aspergillosis

  2019cites this paper
• New pathogens, new tricks: emerging, drug‐resistant fungal pathogens and future prospects for antifungal therapeutics

  2019cites this paper
• Importance of Candida Antigenic Factors: Structure-Driven Immunomodulation Properties of Synthetically Prepared Mannooligosaccharides in RAW264.7 Macrophages

  2019cites this paper
• The Molecular Identification and Antifungal Susceptibilities of Aspergillus Species Causing Otomycosis in Tochigi, Japan

  2018cites this paper
• Optimization of &bgr;‐cyclodextrin consolidated micellar dispersion for promoting the transcorneal permeation of a practically insoluble drug

  2018cites this paper
• Clinical Drug–Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects

  2018cites this paper
• Fungal Infections Complicating Lung Transplantation

  2018cites this paper
• Identification and in Vitro Susceptibility Pattern of Fungal Pathogens in Immunocomprimised Patients with Pulmonary Fungal Infections

  2018cites this paper
• Determining the Susceptibility Pattern of Different Candida Species, Isolated From Hospitalized Immunocompromised Patients in Urmia Hospitals, to Antifungal Drugs

  2018cites this paper
• Invasive Fungal Infections in the Intensive Care Unit.

  2017influential citation
• Aspergillus Terreus Brain Abscess Complicated by Tension Pneumocephalus in a Patient with Angiosarcoma

  2017cites this paper
• Triazole phenotypes and genotypic characterization of clinical Aspergillus fumigatus isolates in China

  2017cites this paper
• PHARMACOKINETICS OF ORALLY ADMINISTERED VORICONAZOLE IN AFRICAN PENGUINS (SPHENISCUS DEMERSUS) AFTER SINGLE AND MULTIPLE DOSES

  2017cites this paper
• In Vitro Susceptibilities of Aspergillus Species to Triazoles and Amphotericin B

  2017cites this paper
• Synthesis, X-ray Single Crystal Structure, Molecular Docking and DFT Computations on N-[(1E)-1-(2H-1,3-Benzodioxol-5-yl)-3-(1H-imidazol-1-yl)propylidene]-hydroxylamine: A New Potential Antifungal Agent Precursor

  2017cites this paper
• Azole resistance in Aspergillus fumigatus: Mechanisms, route of resistance selection, and clinical implications

  2017cites this paper
• Genetics, Molecular, and Proteomics Advances in Filamentous Fungi

  2017cites this paper
• Rapidly progressive rhino-orbito-cerebral mucormycosis in a patient with type 2 diabetes: A case report.

  2017cites this paper
• First description of spontaneous fungal peritonitis caused by Fusarium solani in a critically ill patient with liver cirrhosis

  2017cites this paper
• Species Distribution and In Vitro Azole Susceptibility of Aspergillus Section Nigri Isolates from Clinical and Environmental Settings

  2016cites this paper
• In vitro antifungal susceptibility of clinical species belonging to Aspergillus genus and Rhizopus oryzae.

  2016cites this paper
• Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation.

  2016cites this paper
• Therapeutic drug monitoring of antimicrobials

  2016cites this paper
• Species diversity of Aspergillus section Versicolores in clinical samples and antifungal susceptibility.

  2016cites this paper
• Purpureocillium lilacinum keratitis: a case series and review of the literature.

  2016cites this paper
• Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia

  2016cites this paper
• Determination of Azole Antifungal Drug Resistance Mechanisms Involving Cyp51a Gene in Clinical Isolates of Aspergillus fumigatus and Aspergillus niger

  2016cites this paper
• Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications.

  2016cites this paper
• Potential of Ravuconazole and its Prodrugs as the New OralTherapeutics for Onychomycosis.

  2016cites this paper
• Multigram Scale Synthesis of A21, A New Antibiotic Equally Effective and Less Toxic than Amphotericin B

  2016cites this paper
• Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.

  2016cites this paper
• Rare case of disseminated fusariosis in a young patient with graft vs. host disease following an allogeneic transplant

  2016cites this paper
• Amphotericin B-silver hybrid nanoparticles: synthesis, properties and antifungal activity.

  2016cites this paper
• New record of Scedosporium dehoogii from Chile: Phylogeny and susceptibility profiles to classic and novel putative antifungal agents.

  2016cites this paper
• Oral Antifungal Drugs in the Treatment of Dermatomycosis.

  2016cites this paper
• A Comparative Treatment Study of Intravitreal Voriconazole and Liposomal Amphotericin B in an Aspergillus fumigatus Endophthalmitis Model.

  2015cites this paper
• Efficacy of ravuconazole in a murine model of vaginitis by Candida albicans.

  2015cites this paper
• A n t i f u n g a l A g e n t s Spectrum of Activity, Pharmacology, and Clinical Indications

  2015influential citation
• MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis

  2015cites this paper
• Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification

  2015cites this paper
• Clinical Importance of the Genus Curvularia

  2015cites this paper
• Molecular Epidemiology and In-Vitro Antifungal Susceptibility of Aspergillus terreus Species Complex Isolates in Delhi, India: Evidence of Genetic Diversity by Amplified Fragment Length Polymorphism and Microsatellite Typing

  2015cites this paper
• VORICONAZOLE TOXICITY IN MULTIPLE PENGUIN SPECIES

  2015cites this paper
• Combination Therapy for the Treatment of Mucormycosis: Examining the Evidence

  2015cites this paper
• Glycerol: a more benign and biodegradable promoting medium for catalyst-free one-pot multi-component synthesis of triazolo[1,2- a ]indazole-triones

  2015cites this paper
• Posaconazole: An Update of Its Clinical Use

  2015cites this paper
• Fungal Infections of the Spine

  2015cites this paper
• Studies on Antifungal Potential, Primary Characterization and Mode of Action of a De Novo Cytoplasmic Protein (EAF) from Human Commensal Escherichia coli Against Aspergillus spp.

  2015cites this paper
• Spectrum of Activity, Pharmacology, and Clinical Indications

  2015cites this paper
• Filamentous fungal infections of the cornea: a global overview of epidemiology and drug sensitivity

  2015cites this paper
• Treatment of Disseminated Aspergillosis with Posaconazole in 10 Dogs

  2015cites this paper
• Management of fungal infections in lung transplant recipients

  2015cites this paper
• Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections

  2015cites this paper
• Antifungal wound penetration of amphotericin and voriconazole in combat-related injuries: case report

  2015cites this paper
• Disseminated aspergillosis as the herald manifestation of chronic granulomatous disease in an adult patient.

  2014cites this paper